Your browser doesn't support javascript.
loading
Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
Ahearn, Thomas U; Zhang, Haoyu; Michailidou, Kyriaki; Milne, Roger L; Bolla, Manjeet K; Dennis, Joe; Dunning, Alison M; Lush, Michael; Wang, Qin; Andrulis, Irene L; Anton-Culver, Hoda; Arndt, Volker; Aronson, Kristan J; Auer, Paul L; Augustinsson, Annelie; Baten, Adinda; Becher, Heiko; Behrens, Sabine; Benitez, Javier; Bermisheva, Marina; Blomqvist, Carl; Bojesen, Stig E; Bonanni, Bernardo; Børresen-Dale, Anne-Lise; Brauch, Hiltrud; Brenner, Hermann; Brooks-Wilson, Angela; Brüning, Thomas; Burwinkel, Barbara; Buys, Saundra S; Canzian, Federico; Castelao, Jose E; Chang-Claude, Jenny; Chanock, Stephen J; Chenevix-Trench, Georgia; Clarke, Christine L; Collée, J Margriet; Cox, Angela; Cross, Simon S; Czene, Kamila; Daly, Mary B; Devilee, Peter; Dörk, Thilo; Dwek, Miriam; Eccles, Diana M; Evans, D Gareth; Fasching, Peter A; Figueroa, Jonine; Floris, Giuseppe; Gago-Dominguez, Manuela.
  • Ahearn TU; Division of Cancer Epidemiology and GeneticsDepartment of Health and Human Services, Medical Center Drive, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
  • Zhang H; Division of Cancer Epidemiology and GeneticsDepartment of Health and Human Services, Medical Center Drive, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
  • Michailidou K; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Milne RL; Institute of Neurology & Genetics, Biostatistics Unit, Nicosia, Cyprus.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Dennis J; Cyprus School of Molecular Medicine, Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Dunning AM; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Lush M; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Wang Q; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
  • Andrulis IL; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Anton-Culver H; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Arndt V; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Aronson KJ; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Auer PL; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Augustinsson A; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  • Baten A; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Becher H; Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Behrens S; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Benitez J; Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Bermisheva M; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Blomqvist C; Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  • Bojesen SE; Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.
  • Bonanni B; Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Børresen-Dale AL; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Brauch H; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Brenner H; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Brooks-Wilson A; Biomedical Network On Rare Diseases (CIBERER), Madrid, Spain.
  • Brüning T; Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.
  • Burwinkel B; Saint Petersburg State University, Saint-Petersburg, Russia.
  • Buys SS; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Canzian F; Department of Oncology, Örebro University Hospital, Örebro, Sweden.
  • Castelao JE; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Chang-Claude J; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Chanock SJ; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Chenevix-Trench G; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Clarke CL; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
  • Collée JM; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Cox A; iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany.
  • Cross SS; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.
  • Czene K; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Daly MB; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Devilee P; Division of Preventive Oncology, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Dörk T; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
  • Dwek M; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
  • Eccles DM; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute, Ruhr University Bochum (IPA), Bochum, Germany.
  • Evans DG; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), C080, Heidelberg, Germany.
  • Fasching PA; Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.
  • Figueroa J; Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA.
  • Floris G; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Gago-Dominguez M; Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
Breast Cancer Res ; 24(1): 2, 2022 01 04.
Article en En | MEDLINE | ID: mdl-34983606
ABSTRACT

BACKGROUND:

Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear.

METHODS:

Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes.

RESULTS:

Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate < 5%), most commonly ER and grade, followed by PR and HER2. Models for intrinsic-like subtypes found nearly all of these variants (83 of 85) associated at p < 0.05 with risk for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants associated with triple-negative (TN) disease. Ten variants were associated with risk of all subtypes in different magnitude. Five variants were associated with risk of luminal A-like and TN subtypes in opposite directions.

CONCLUSION:

This report demonstrates a high level of complexity in the etiology heterogeneity of breast cancer susceptibility variants and can inform investigations of subtype-specific risk prediction.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article